Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

According to the most common co-mutations including serine/threonine kinase 11/liver kinase B1, TP53 and cyclin-dependent kinase inhibitor 2A/B inactivation, KRAS-mutant NSCLC has been classified into three subsets: KL, KP, and KC. [15] Response to MEKi may also be different due to downstream activa...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2020-10, Vol.133 (20), p.2495-2497
Main Authors: Xu, Jia-Li, Wang, Xin-Zhu, Jiang, Hu-Ning, Chen, Yi, Wang, Rong, Shu, Yong-Qian
Format: Article
Language:English
Subjects:
Antibodies
Apoptosis
Cancer therapies
Clinical trials
Cyclin-dependent kinases
Immune system
Immunotherapy
Kinases
Lung cancer
Lymphocytes
Medical Progress
Melanoma
Metastasis
Mutation
Proteins
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the most common co-mutations including serine/threonine kinase 11/liver kinase B1, TP53 and cyclin-dependent kinase inhibitor 2A/B inactivation, KRAS-mutant NSCLC has been classified into three subsets: KL, KP, and KC. [15] Response to MEKi may also be different due to downstream activation of AKT or signal transducer and activator of transcription 3. [...]a proper signature predicting the response to combination therapies with MEKi and checkpoint inhibitors is required in KRAS-mutant NSCLC. [...]optimization strategies of combination therapies in NSCLC need further evaluation.
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000001070